Allogene Therapeutics (ALLO)

Executive Summary

Allogene Therapeutics is a clinical-stage biotechnology company pioneering off-the-shelf allogeneic CAR T cell therapies. Its proprietary AlloCAR T platform leverages multiplex gene-editing to overcome immune rejection and enable scalable manufacturing. The lead product, cemacabtagene ansegedleucel (cema-cel), is being evaluated in a Phase 2 trial for frontline large B-cell lymphoma (LBCL), with the potential to challenge autologous CAR Ts. Additional pipeline assets include ALLO-316 targeting CD70 in advanced clear cell renal cell carcinoma (ccRCC) and ALLO-329 for autoimmune diseases. Despite prior setbacks in relapsed/refractory settings, Allogene's focus on earlier lines and novel indications aims to differentiate its platform. The company faces significant competition but benefits from a strong balance sheet and partnerships. Execution on clinical milestones will be critical for value inflection.

Upcoming Catalysts (preview)

• Q3 2026Cema-cel frontline LBCL Phase 2 interim data50% success
• Q2 2026ALLO-316 Phase 1 ccRCC data update60% success
• Q4 2026ALLO-329 autoimmune disease Phase 1 initial data40% success